Company Description
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy.
The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder.
The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.
The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.
Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
| Country | United States |
| Founded | 2006 |
| IPO Date | Apr 16, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Neil McFarlane |
Contact Details
Address: 1180 Celebration Boulevard, Suite 103 Celebration, Florida 34747 United States | |
| Phone | 321 939 3416 |
| Website | zevra.com |
Stock Details
| Ticker Symbol | ZVRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434647 |
| ISIN Number | US4884452065 |
| Employer ID | 20-5894398 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil F. McFarlane | President, Chief Executive Officer and Director |
| R. LaDuane Clifton CPA | Chief Financial Officer and Treasurer |
| Joshua M. Schafer M.B.A. | Chief Commercial Officer |
| Nichol L. Ochsner | Vice President of Investor Relations and Corporate Communications |
| Rahsaan W. Thompson J.D. | Chief Legal Officer, Secretary and Compliance Officer |
| Alison Peters | Chief People Officer |
| Dr. Christopher M. Lauderback Ph.D. | Senior Vice President of Manufacturing |
| Dr. Adrian Quartel FFPM, M.D. | Chief Medical Officer |
| Gerald J. Orehostky | Senior Vice President of Regulatory Affairs and Quality |
| Tanya Hayden | Senior Vice President and Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | PRRN14A | Filing |
| Apr 23, 2025 | DFAN14A | Filing |
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | DEFC14A | Filing |
| Apr 16, 2025 | PRRN14A | Filing |
| Apr 10, 2025 | PREC14A | Filing |
| Apr 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 7, 2025 | 8-K | Current Report |
| Mar 31, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |